Peptides News and Research

RSS

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

Esperance initiates enrollment in EP-100 and paclitaxel Phase 2 combination trial for ovarian cancer

Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer.

18 May 2012

Insight into why diabetics suffer from increased pain and temperature sensitivity

Why diabetics suffer from increased pain and temperature sensitivity is a step closer to being understood and effectively treated.

17 May 2012

TJU researchers to investigate Cu-64 imaging agent for prostate cancer

Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.

17 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Researchers uncover new way to stimulate activity of immune cell opiate receptors

Researchers at Rutgers University have uncovered a new way to stimulate activity of immune cell opiate receptors, leading to efficient tumor cell clearance.

14 May 2012

Helix BioMedix first quarter revenue up 90% to $680,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the first quarter ended March 31, 2012.

11 May 2012

Discovery Labs reports data from SURFAXIN preclinical study on RDS

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.

10 May 2012

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

Wan-Pei Su, a graduate student of Molecular Medicine at National Cheng Kung University (NCKU), southern Taiwan, has received a Graduate/Postdoctoral Travel Award from the American Society for Biochemistry and Molecular Biology (ASBMB) to attend the annual conference on Experimental Biology (EB) in San Diego in April 2012.

10 May 2012

iBio receives U.S. patent for iBioModulator platform

iBio, Inc. today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator platform.

9 May 2012

Unigene first quarter net loss decreases to $6.0 million

Unigene Laboratories, Inc., today announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Dilp8 provides an important signal to slow body growth and delay insect development

Two independent groups of researchers have identified a hormone that is responsible for keeping the growth and development of insects on track. The results, which are reported in the journal Science, suggest that Dilp8 provides an important signal to slow body growth and delay insect development.

5 May 2012

Therapy to halt symptoms in Parkinson's patients

Parkinson's disease, a disorder which affects movement and cognition, affects over a million Americans, including actor Michael J. Fox, who first brought it to the attention of many TV-watching Americans. It's characterized by a gradual loss of neurons that produce dopamine. Mutations in the gene known as DJ-1 lead to accelerated loss of dopaminergic neurons and result in the onset of Parkinson's symptoms at a young age.

3 May 2012

NJIT professor receives $340,000 NIH grant to investigate membrane proteins

NJIT Associate Professor Edgardo Farinas has been awarded today a three-year $340,000 National Institutes of Health (NIH) grant to investigate spores as a protein display platform for the directed evolution of membrane proteins.

3 May 2012

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Probiodrug AG (Probiodrug), a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease (AD), today announced its scientists and academics collaborators published seminal findings on the role of pyroglu Aβ in AD pathology in the May 2, 2012 online edition of the journal Nature (DOI: 10.1038/nature11060). The new findings add to the growing body of evidence that pyroglu Aβ plays a crucial role in the initiation of AD. In addition, the research results further elucidate the mechanism by which pyroglu Aβ triggers neuronal toxicity.

3 May 2012

Expression of tyrosine kinases may limit effectiveness of agents against sarcomas

To better understand the signaling pathways active in sarcomas, researchers at Moffitt Cancer Center used state-of-the-art mass spectrometry-based proteomics to characterize a family of protein enzymes that act as "on" or "off" switches important in the biology of cancer. The tyrosine kinases they identified, the researchers said, could act as "drivers" for the growth and survival of sarcomas.

2 May 2012

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Novo Nordisk granted exclusive rights to Caisson's heparosan-based drug delivery technology

Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, announced today that it has entered into a Development and License Agreement with Novo Nordisk A/S, a global healthcare company and leader in diabetes care.

From Novo Nordisk 2 May 2012

Peptides News and Research

Gattex may represent new treatment approach for short bowel syndrome

Sigmoid provides financial and product development update

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

Esperance initiates enrollment in EP-100 and paclitaxel Phase 2 combination trial for ovarian cancer

Insight into why diabetics suffer from increased pain and temperature sensitivity

TJU researchers to investigate Cu-64 imaging agent for prostate cancer

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Researchers uncover new way to stimulate activity of immune cell opiate receptors

Helix BioMedix first quarter revenue up 90% to $680,000

Discovery Labs reports data from SURFAXIN preclinical study on RDS

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

iBio receives U.S. patent for iBioModulator platform

Unigene first quarter net loss decreases to $6.0 million

Dilp8 provides an important signal to slow body growth and delay insect development

Therapy to halt symptoms in Parkinson's patients

NJIT professor receives $340,000 NIH grant to investigate membrane proteins

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Expression of tyrosine kinases may limit effectiveness of agents against sarcomas

Lower rate of reintubation observed in infants receiving SURFAXIN

Novo Nordisk granted exclusive rights to Caisson's heparosan-based drug delivery technology

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News